Leiomyosarcoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Clinical Trials

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Conditions:   Metastatic Leiomyosarcoma;   Metastatic Sarcoma;   Metastatic Soft Tissue Sarcoma;   Unresectable Leiomyosarcoma;   Unresectable Sarcoma;   Unresectable Soft Tissue Sarcoma Interventions:   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Peposertib Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Condition:   Soft Tissue Sarcoma Interventions:   Drug: ADI PEG20;   Other: Placebo Sponsor:   Polaris Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Conditions:   Metastatic Leiomyosarcoma;   Metastatic Sarcoma;   Metastatic Soft Tissue Sarcoma;   Unresectable Leiomyosarcoma;   Unresectable Sarcoma;   Unresectable Soft Tissue Sarcoma Interventions:   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Peposertib Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Condition:   Soft Tissue Sarcoma Interventions:   Drug: ADI PEG20;   Other: Placebo Sponsor:   Polaris Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Conditions:   Metastatic Leiomyosarcoma;   Metastatic Sarcoma;   Metastatic Soft Tissue Sarcoma;   Unresectable Leiomyosarcoma;   Unresectable Sarcoma;   Unresectable Soft Tissue Sarcoma Interventions:   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Peposertib Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Condition:   Soft Tissue Sarcoma Interventions:   Drug: ADI PEG20;   Other: Placebo Sponsor:   Polaris Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Conditions:   Metastatic Leiomyosarcoma;   Metastatic Sarcoma;   Metastatic Soft Tissue Sarcoma;   Unresectable Leiomyosarcoma;   Unresectable Sarcoma;   Unresectable Soft Tissue Sarcoma Interventions:   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Peposertib Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Condition:   Soft Tissue Sarcoma Interventions:   Drug: ADI PEG20;   Other: Placebo Sponsor:   Polaris Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Conditions:   Metastatic Leiomyosarcoma;   Metastatic Sarcoma;   Metastatic Soft Tissue Sarcoma;   Unresectable Leiomyosarcoma;   Unresectable Sarcoma;   Unresectable Soft Tissue Sarcoma Interventions:   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Peposertib Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Condition:   Soft Tissue Sarcoma Interventions:   Drug: ADI PEG20;   Other: Placebo Sponsor:   Polaris Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Conditions:   Metastatic Leiomyosarcoma;   Metastatic Sarcoma;   Metastatic Soft Tissue Sarcoma;   Unresectable Leiomyosarcoma;   Unresectable Sarcoma;   Unresectable Soft Tissue Sarcoma Interventions:   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Peposertib Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Condition:   Soft Tissue Sarcoma Interventions:   Drug: ADI PEG20;   Other: Placebo Sponsor:   Polaris Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Conditions:   Metastatic Leiomyosarcoma;   Metastatic Sarcoma;   Metastatic Soft Tissue Sarcoma;   Unresectable Leiomyosarcoma;   Unresectable Sarcoma;   Unresectable Soft Tissue Sarcoma Interventions:   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Peposertib Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Condition:   Soft Tissue Sarcoma Interventions:   Drug: ADI PEG20;   Other: Placebo Sponsor:   Polaris Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Conditions:   Metastatic Leiomyosarcoma;   Metastatic Sarcoma;   Metastatic Soft Tissue Sarcoma;   Unresectable Leiomyosarcoma;   Unresectable Sarcoma;   Unresectable Soft Tissue Sarcoma Interventions:   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Peposertib Sponsor:   National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 3, 2023 Category: Research Source Type: clinical trials